Previous 10 | Next 10 |
Neurocrine Biosciences to Present New Data Analyses of Once-Daily ONGENTYS® (opicapone) in Patients with Parkinson's Disease at the American Neurological Association 2020 Virtual Meeting - ONGENTYS, the First and Only Once-Daily COMT Inhibitor, Led to Greater Reductions in ...
AXGT has promising gene therapy results in Parkinson's Disease. If future clinical results mimic the early ones, AXGT could have an addressable market of over $7.5 billion. Trading at an enterprise value of $143M, the risk reward ratio is enticing. Nonetheless, investors sho...
Neurocrine presents encouraging three-year data for Parkinson’s treatment Neurocrine Biosciences Inc. ( NBIX ) reported that its data from PD-1101 study has demonstrated sustained improvement in motor function in patients with Parkinson’s disease. This Phase Ib open-label, th...
Neurocrine Biosciences (NBIX) has been on my radar for a while as a high-quality company to watch due to its execution with Ingrezza, growing revenues and earnings, and productive use of cash flow by expanding the pipeline and thus potential future cash flows. I previously wrote about Neurocri...
I had previously expressed my concern that Neurocrine ( NBIX ) shares could remain weak given a lack of thesis-changing data catalysts on the horizon, and the shares have fallen another 17% since my last update. I see nothing wrong with the business, but the quality of the Ingrezza business ...
Back in April, Neurocrine Biosciences (NASDAQ: NBIX) won Food and Drug Administration approval for its new drug Ogentys to be used in conjunction with Parkinson's disease treatment levodopa, but its launch was delayed by the COVID-19 pandemic. Now, the drug is finally hitting the market. ...
SAN DIEGO , Sept. 14, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that 50 mg capsules of ONGENTYS ® (opicapone), the first and only FDA-approved once-daily catechol-O-methyltransferase (COMT) inhibitor, are now available by prescription in ...
Collaboration partners, Neurocrine Biosciences (NASDAQ: NBIX) and Voyager Therapeutics (NASDAQ: VYGR) announced data from an early stage clinical trial with Parkinson's disease patients and NBIb-1817, an experimental gene therapy. Three years after a single administration, 14 out of...
Neurocrine Biosciences ( NBIX -3.8% ) and Voyager Therapeutics ( VYGR -1.5% ) announced data from Phase Ib (PD-1101) three-year efficacy and safety study, demonstrating that a one-time treatment with NBIb-1817 (VY-AADC) showed sustained improvement in motor function including...
-- Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 -- NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater “On” Time without Troublesome Dyskinesia and Reduction in Unified ...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...